Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL - Get Free Report) saw a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 20,200 shares, an increase of 37.4% from the November 15th total of 14,700 shares. Based on an average daily trading volume, of 19,000 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.6% of the company's shares are short sold.
Cryo-Cell International Price Performance
Cryo-Cell International stock traded down $0.07 during midday trading on Friday, reaching $7.84. The stock had a trading volume of 6,563 shares, compared to its average volume of 11,139. The firm has a market capitalization of $63.15 million, a price-to-earnings ratio of -7.39 and a beta of 0.49. Cryo-Cell International has a 12 month low of $4.47 and a 12 month high of $9.50.
Cryo-Cell International (NYSEAMERICAN:CCEL - Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.11. Cryo-Cell International had a negative net margin of 28.03% and a negative return on equity of 42.06%. The business had revenue of $8.07 million during the quarter.
Cryo-Cell International Dividend Announcement
The business also recently declared a -- dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a $0.25 dividend. The ex-dividend date was Friday, November 15th. Cryo-Cell International's payout ratio is currently -94.34%.
Institutional Trading of Cryo-Cell International
An institutional investor recently raised its position in Cryo-Cell International stock. Geode Capital Management LLC lifted its holdings in shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL - Free Report) by 68.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,860 shares of the company's stock after acquiring an additional 16,203 shares during the quarter. Geode Capital Management LLC owned 0.49% of Cryo-Cell International worth $254,000 at the end of the most recent quarter. Institutional investors own 10.44% of the company's stock.
About Cryo-Cell International
(
Get Free Report)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.
Recommended Stories
Before you consider Cryo-Cell International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryo-Cell International wasn't on the list.
While Cryo-Cell International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
